Logo
Nexfill Sub Q

Nexfill Sub Q

Nexfill

Dermal fillers
  • CE Marked hyaluronic acid dermal filler (medical device) for use in the EU/UK and other CE Recognising markets.
  • KFDA/MFDS approval in South Korea for hyaluronic acid filler indications (as stated by manufacturer and distributors).
  • Manufactured under medical device quality standards consistent with international requirements for injectable HA fillers, including documented CE certification with an EU representative in Germany.
Monophasic cross-linked hyaluronic acid dermal filler for deep volumizing and facial contouring (Sub-Q)

Description

Nexfill Sub Q is a high-density, monophasic hyaluronic acid dermal filler designed for deep injection and structural volumizing of the cheeks, chin, jawline and other areas with significant volume loss, providing sculpted contours and correction of deep wrinkles while maintaining natural-looking results.

Bnefits

  • Adds significant volume to sunken cheeks, chins and temples.
  • High-quality hyaluronic acid gel for seamless tissue integration and minimal visibility.
  • Formulated with approximately 60% less BDDE than typical industry fillers to reduce post-injection swelling.
  • Provides deep hydration and moisture retention for a plumper, more youthful appearance.
  • High viscoelasticity for strong structural support and long-lasting volume.
  • Monophasic, smooth gel that is easily moldable and reversible with hyaluronidase.
  • CE-marked filler manufactured under medical device quality standards.

Indications

  • Restoration of volume in cheeks
  • Temporal hollowing (temples)
  • Chin and jawline augmentation and contouring
  • Deep nasolabial folds
  • Marionette lines
  • Facial volumization in areas requiring significant structure and definition (for example cheeks, chin, nose and jawline), in accordance with the Instructions for Use and local regulations

Composition

  • Hyaluronic Acid 24 mg/ml (cross-linked, non-animal source)
  • Lidocaine 0.3% (local anaesthetic)
  • BDDE (1,4-butanediol diglycidyl ether) as cross-linking agent – reduced content (approximately 60% less than typical industry levels, not detected in some analytical tests according to manufacturer data)

Formulation

  • Monophasic, cross-linked hyaluronic acid gel with lidocaine for Sub-Q (deep) injection
  • Ultra High Density (UHD) technology with combined chemical and mechanical cross-linking to achieve high viscoelasticity and cohesion
  • Smooth, homogeneous gel designed for deep volumizing and contouring of the face

Packaging

  • Box containing 1 x 1 mL pre-filled sterile syringe of Nexfill Sub Q
  • Each syringe supplied sterile; needles supplied may vary by distributor – refer to local pack and Instructions for Use
  • Available commercial pack options from certain distributors: 1 box, 5 boxes, 10 boxes, 20 boxes

Usage

  • For use only by trained, qualified and appropriately insured medical/aesthetic professionals in accordance with local laws and regulations.
  • Indicated for deep dermal or subcutaneous injection in the specified facial treatment areas; the exact injection plane, technique and volume per site must follow the manufacturer’s Instructions for Use (IFU) and clinical training.
  • Use aseptic technique throughout preparation and injection; do not use if the blister pack, syringe or tamper-evident seals are damaged or previously opened.
  • Inject slowly with low, even pressure, aspirating according to the practitioner’s protocol to minimise the risk of intravascular injection.
  • Do not overcorrect; allow for initial post-treatment swelling when assessing correction.
  • After treatment, advise patients to avoid makeup, saunas, intense heat, strenuous exercise and alcohol for a short period as per clinic protocol, and to follow all post-procedure instructions.
  • Do not re-sterilise or reuse the syringe or any single-use accessories.
  • Always refer to the latest official Nexfill IFU and local clinical guidelines for full directions for use.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or any of the excipients in the formulation.
  • History of severe anaphylactic reactions or multiple severe allergies.
  • Presence of active skin disease, inflammation, infection or herpes lesions at or near the planned injection sites.
  • Patients with bleeding disorders, uncontrolled systemic disease or those receiving anticoagulant or antiplatelet therapy where injection risks cannot be appropriately managed.
  • Autoimmune diseases or immunocompromised states unless, in the prescriber’s judgement, potential benefits outweigh risks and the patient is closely monitored.
  • Pregnant or breastfeeding patients, due to lack of safety data.
  • Patients under 18 years of age.
  • Previous permanent or non-hyaluronic-acid fillers in the planned treatment area, unless the practitioner has specific expertise and has assessed the risks.
  • Any other contraindications listed in the official manufacturer’s Instructions for Use.

Adverse Effects

  • Common, usually transient reactions at the injection site such as redness (erythema), swelling, tenderness or pain, bruising, itching, firmness or lumps/bumps.
  • Local oedema, induration or palpable nodules or unevenness in the treated area.
  • Temporary changes in skin colour (hyperpigmentation or hypopigmentation) at the injection site.
  • Injection-related bleeding or haematoma.
  • Infection at the injection site, including abscess formation in rare cases.
  • Hypersensitivity reactions, including immediate or delayed-onset allergic responses.
  • Granuloma formation or inflammatory nodules.
  • Very rare but serious complications associated with intravascular injection such as vascular occlusion, skin ischaemia/necrosis, or visual disturbances including blindness, particularly when injecting in high-risk areas.
  • Any additional adverse effects described in the official Instructions for Use should be reviewed with the patient as part of informed consent.

Storage Conditions

  • Store between 2°C and 25°C (do not freeze).
  • Keep away from direct sunlight and sources of heat.
  • Store in the original blister and outer packaging until use to maintain sterility and protect from light.
  • Do not use after the expiry date printed on the packaging.
  • Do not use if the product has been improperly stored (for example exposed to extreme temperatures) or if there are visible defects in the syringe or solution (such as discoloration or particles).

Duration

Approximate longevity of results is typically 12\u201318 months in deep volumizing indications, depending on the treatment area, product volume used, injection technique and patient-specific factors such as metabolism and lifestyle.

Onset

Immediate visible volumizing and contouring effect after injection, with final aesthetic outcome apparent once initial swelling and redness resolve over several days.

Browse more Dermal fillers

Top Treatments

Top Cities in the UK